Immune Thrombocytopenia
182
35
41
51
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
13 trials with published results (7%)
Research Maturity
51 completed trials (28% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
2.7%
5 terminated out of 182 trials
91.1%
+4.5% vs benchmark
25%
46 trials in Phase 3/4
25%
13 of 51 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 51 completed trials
Clinical Trials (182)
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
A Real World Study of Treatment Patterns and Effectiveness of Standard of Care in Primary Immune Thrombocytopenia Patients
Selective Mediterranean Diet in Immune Thrombocytopenia
A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag
Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia
Universal STAR-T Cell Injection in R/R Autoimmune Diseases.
ATRA for Management of Primary ITP
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP